Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia (2012)
- Authors:
- Levin, Raquel - Universidade Federal de São Paulo (UNIFESP)
- Almeida, Valéria - Universidade Federal de São Paulo (UNIFESP)
- Peres, Fernanda Fiel - Universidade Federal de São Paulo (UNIFESP)
- Calzavara, Mariana Bendlin - Universidade Federal de São Paulo (UNIFESP)
- Silva, Neide Derci da - Universidade Federal de São Paulo (UNIFESP)
- Suiama, Mayra Akimi - Universidade Federal de São Paulo (UNIFESP)
- Niigaki, Suzie Tamie - Universidade Federal de São Paulo (UNIFESP)
- Zuardi, Antonio Waldo
- Hallak, Jaime Eduardo Cecílio
- Crippa, José Alexandre de Souza
- Abilio, Vanessa Costhek - Universidade Federal de São Paulo (UNIFESP)
- USP affiliated authors: CRIPPA, JOSÉ ALEXANDRE DE SOUZA - FMRP ; ZUARDI, ANTONIO WALDO - FMRP ; HALLAK, JAIME EDUARDO CECILIO - FMRP
- Unidade: FMRP
- Subjects: CANNABIS (COMPONENTES;FARMACOLOGIA); ANTAGONISMO DE DROGAS; MODELOS ANIMAIS DE DOENÇAS; ESQUIZOFRENIA
- Language: Inglês
- Imprenta:
- Source:
- Título: Current Pharmaceutical Design
- ISSN: 1381-6128
- Volume/Número/Paginação/Ano: v. 18, n. 32, p. 4960-4965, 2012
-
ABNT
LEVIN, Raquel et al. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Current Pharmaceutical Design, v. 18, n. 32, p. 4960-4965, 2012Tradução . . Acesso em: 11 mar. 2026. -
APA
Levin, R., Almeida, V., Peres, F. F., Calzavara, M. B., Silva, N. D. da, Suiama, M. A., et al. (2012). Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Current Pharmaceutical Design, 18( 32), 4960-4965. -
NLM
Levin R, Almeida V, Peres FF, Calzavara MB, Silva ND da, Suiama MA, Niigaki ST, Zuardi AW, Hallak JEC, Crippa JA de S, Abilio VC. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Current Pharmaceutical Design. 2012 ; 18( 32): 4960-4965.[citado 2026 mar. 11 ] -
Vancouver
Levin R, Almeida V, Peres FF, Calzavara MB, Silva ND da, Suiama MA, Niigaki ST, Zuardi AW, Hallak JEC, Crippa JA de S, Abilio VC. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. Current Pharmaceutical Design. 2012 ; 18( 32): 4960-4965.[citado 2026 mar. 11 ] - Cannabidiol and neuroprotection: evidence from preclinical studies
- Cannabidiol displays proteomic similarities to antipsychotics in cuprizone-exposed human oligodendrocytic cell line MO3.13
- Marijuana, feijoada and the debate on drug legalization
- Cannabidiol for the treatment of psychosis in Parkinson's disease
- Δ9-THC intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy: full remission after switching to purified cannabidiol
- Administration of harmine and imipramine alters creatine kinase and mitochondrial respiratory chain activities in the rat brain
- Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders
- Cannabidiol administered during peri-adolescence prevents behavioral abnormalities in an animal model of schizophrenia
- Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system
- Cannabidiol reverses memory impairments and activates components of the Akt/GSK3β pathway in an experimental model of estrogen depletion
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
